Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Rhea-AI Summary

Nuvectis Pharma, a biopharmaceutical company focused on innovative oncology treatments, announced that CEO Ron Bentsur will present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City. The conference is scheduled for May 2, 2022, at 12:00 PM Eastern Time. Nuvectis is advancing two drug candidates: NXP800, for platinum-resistant, ARID1a-mutated ovarian carcinoma, which has received FDA Fast Track Designation, and NXP900, a SRC/YES1 kinase inhibitor with a pending IND application.

The company's commitment to addressing unmet medical needs in oncology highlights the significance of their innovative approaches in developing precision medicines.

FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Investor Conference at the NASDAQ world headquarters in New York City.

Event	H.C. Wainwright BioConnect Investor Conference at NASDAQ
Date	May 2nd, 2022
Time	12:00 PM Eastern Time
Link	https://journey.ct.events

About Nuvectis Pharma

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is a clinical-stage, oral small molecule under development for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma and additional solid tumor types. The United States Food and Drug Administration (“FDA”) granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor with an Investigational New Drug (“IND”) application pending.

Nuvectis Pharma Contact:

Ron Bentsur
Chairman, Chief Executive Officer and President
Tel: 201-614-3151
rbentsur@nuvectis.com

Media Relations Contact:

Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
ccalabrese@lifesciadvisors.com

FAQ

What is the date and time of Nuvectis Pharma's presentation at the H.C. Wainwright BioConnect Investor Conference?

Nuvectis Pharma's presentation is scheduled for May 2, 2022, at 12:00 PM Eastern Time.

Where will the H.C. Wainwright BioConnect Investor Conference take place?

The conference will take place at NASDAQ in New York City.

What are the key drug candidates being developed by Nuvectis Pharma?

Nuvectis Pharma is developing NXP800 and NXP900.

What is NXP800 used for?

NXP800 is being developed for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma.

What designation has the FDA granted to NXP800?

The FDA has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma.

What is NXP900?

NXP900 is a novel small molecule SRC/YES1 kinase inhibitor with an Investigational New Drug application pending.